Literature DB >> 21272562

Liver kinase B1 (LKB1) in the pathogenesis of UVB-induced murine basal cell carcinoma.

Yevgeniya A Byekova1, Jennifer L Herrmann, Jianmin Xu, Craig A Elmets, Mohammad Athar.   

Abstract

LKB1, a known tumor suppressor, is mutated in Peutz-Jeghers Syndrome (PJS). It is responsible for the enhanced cancer risk in patients with PJS. Dysregulation of LKB1-dependent signaling also occurs in various epithelial cancers. UVB alters the expression of LKB1, though its role in the pathogenesis of skin cancer is unknown. Here we describe upregulation of LKB1 expression in UVB-induced murine basal cell carcinoma (BCC) and in human skin tumor keratinocytes. AMP-kinase and acetyl Co-A carboxylase, the downstream LKB1 targets, are also enhanced in this neoplasm. In addition, p-Akt, a kinase which inactivates GSK3β by its phosphorylation, is enhanced in BCCs. Consistently, an accumulation of p-GSK3β and an increase in activated nuclear β-catenin are found. mTOR signaling, which is also inhibited by LKB1, remains upregulated in BCCs. However, a marked decrease in the expression of sestrins, which function as potent negative regulators of mTOR is observed. Metformin, a known chemical inducer of this pathway, was found effective in immortalized HaCaT keratinocytes, but failed to activate the LKB1-dependent signaling in human carcinoma A431 cells. Thus, our data show that the LKB1/AMPK axis fails to regulate mTOR pathway, and a complex regulatory mechanism exists for the persistent mTOR activation in murine BCCs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272562      PMCID: PMC3072754          DOI: 10.1016/j.abb.2011.01.006

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  40 in total

1.  Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation.

Authors:  G Saldanha; V Ghura; L Potter; A Fletcher
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

2.  Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.

Authors:  Leslie J Christenson; Theresa A Borrowman; Celine M Vachon; Megha M Tollefson; Clark C Otley; Amy L Weaver; Randall K Roenigk
Journal:  JAMA       Date:  2005-08-10       Impact factor: 56.272

3.  UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes.

Authors:  D Peus; R A Vasa; A Beyerle; A Meves; C Krautmacher; M R Pittelkow
Journal:  J Invest Dermatol       Date:  1999-05       Impact factor: 8.551

4.  Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis.

Authors:  Mohammad Athar; Chengxin Li; Xiuwei Tang; Sumin Chi; Xiaoli Zhang; Arianna L Kim; Stephen K Tyring; Levy Kopelovich; Jennifer Hebert; Ervin H Epstein; David R Bickers; Jingwu Xie
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Basal cell carcinomas in mice overexpressing sonic hedgehog.

Authors:  A E Oro; K M Higgins; Z Hu; J M Bonifas; E H Epstein; M P Scott
Journal:  Science       Date:  1997-05-02       Impact factor: 47.728

6.  LKB1 (XEEK1) regulates Wnt signalling in vertebrate development.

Authors:  Olga Ossipova; Nabeel Bardeesy; Ronald A DePinho; Jeremy B A Green
Journal:  Nat Cell Biol       Date:  2003-09-14       Impact factor: 28.824

7.  TSC2 mediates cellular energy response to control cell growth and survival.

Authors:  Ken Inoki; Tianqing Zhu; Kun-Liang Guan
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

8.  Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer.

Authors:  A Ylikorkala; E Avizienyte; I P Tomlinson; M Tiainen; S Roth; A Loukola; A Hemminki; M Johansson; P Sistonen; D Markie; K Neale; R Phillips; P Zauber; T Twama; J Sampson; H Järvinen; T P Mäkelä; L A Aaltonen
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

9.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

10.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Authors:  Michael N Corradetti; Ken Inoki; Nabeel Bardeesy; Ronald A DePinho; Kun-Liang Guan
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

View more
  5 in total

1.  Metformin inhibits the proliferation of A431 cells by modulating the PI3K/Akt signaling pathway.

Authors:  Yingshan Liu; Yan Zhang; Kun Jia; Yuhao Dong; Weiyuan Ma
Journal:  Exp Ther Med       Date:  2015-01-27       Impact factor: 2.447

2.  LKB1 suppresses androgen synthesis in a mouse model of hyperandrogenism via IGF-1 signaling.

Authors:  Ying Xu; Yongxing Gao; Zufang Huang; Yan Zheng; Wenjuan Teng; Deyan Zheng; Xiaohua Zheng
Journal:  FEBS Open Bio       Date:  2019-09-12       Impact factor: 2.693

3.  GSK3β signaling is involved in ultraviolet B-induced activation of autophagy in epidermal cells.

Authors:  Yang Yang; Haiping Wang; Siying Wang; Mei Xu; Mei Liu; Mingjun Liao; Jacqueline A Frank; Sabal Adhikari; Kimberly A Bower; Xianglin Shi; Cuiling Ma; Jia Luo
Journal:  Int J Oncol       Date:  2012-09-05       Impact factor: 5.650

4.  Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.

Authors:  Bruna Corominas-Faja; Rosa Quirantes-Piné; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Sílvia Cufí; Begoña Martin-Castillo; Vicente Micol; Jorge Joven; Antonio Segura-Carretero; Javier A Menendez
Journal:  Aging (Albany NY)       Date:  2012-07       Impact factor: 5.682

5.  Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy.

Authors:  Inyoung Kim; Yu-Ying He
Journal:  Front Oncol       Date:  2013-07-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.